SEMAGLUTIDE VIAL 7-12 BUNDLE OPTIONS

The trial realized the two its Most important endpoints, with semaglutide 2.four mg demonstrating statistically important and outstanding improvements in liver fibrosis without any worsening of steatohepatitis, and resolution of steatohepatitis without any worsening of liver fibrosis in people with MASH as compared to placebo.1Inactive ingredients: